On May 21, 2026, Immix Biopharma, Inc. revealed the pricing details of its underwritten registered offering, consisting of 16,778,524 shares of common stock priced at $8.94 per share for a total public price of $150 million, excluding underwriting discounts and expenses. The offering is set to conclude around May 22, 2026, pending the fulfillment of standard closing conditions.